New Opioids May Need Comparative Effectiveness Data For Approval

Draft guidance says US FDA will consider product's benefit-risk balance relative to approved analgesics; it is particularly interested in comparative efficacy and safety data.

Closeup of risk and benefit wooden blocks on seesaw against gray background - Image

The US Food and Drug Administration will be evaluating whether proposed new opioid analgesics provide any advantages over existing pain therapeutics and could make it a requirement for approval. The agency also will be considering if a proposed product has any comparative safety and efficacy data.

The agency issued draft guidance on 20 June describing the benefit-risk assessment it uses in evaluating applications for opioid analgesic...

Pink Sheet Podcast

Learn what's happening at the US FDA. On the go.

Derrick Gingery and the team bring you a weekly "Drug Fix".

More from US FDA

More from Agency Leadership